Novo Nordisk A/S (NYSE: NVO ) on Tuesday announced a strategic partnership with OpenAI aimed at accelerating drug development and advancing the use of artificial intelligence across its operations, positioning the company to bring treatments to patients faster. AI To Accelerate Drug Discovery The collaboration will leverage advanced AI tools to analyze complex datasets, identify promising drug candidates, and streamline the transition from early-stage research to clinical application. The initiative is designed to reduce development timelines, a critical factor in improving patient access to new therapies. The partnership includes built-in safeguards such as strict data protection protocols, governance frameworks, and human oversight to ensure ethical and compliant deployment of AI technologies. "Integrating AI in our everyday work gives us the ability to analyze datasets at a scale ... Full story available on Benzinga.com
Novo Nordisk Expands AI Push With ChatGPT Parent OpenAI
